ArticleJournal of the American Society of Nephrology : JASN2020
Amphiregulin Aggravates Glomerulonephritis
Article in Journal of the American Society of Nephrology : JASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity.Molecular oncology · 2026Article
- Foxp3Research square · 2025Article
- Amphiregulin in Fibrotic Diseases and Cancer.International journal of molecular sciences · 2025Review
- Treg derived Amphiregulin protects from murine lupus nephritis via tissue reparative effects.Scientific reports · 2025Article
- Associations of Serum Amphiregulin Levels With Kidney Failure and Mortality: The Chronic Renal Insufficiency Cohort (CRIC).Kidney medicine · 2025Article
- The amphiregulin- epidermal growth factor receptor axis as a therapeutic target in sepsis.Frontiers in immunology · 2025Observational
- Clinical significance of amphiregulin in patients with chronic kidney disease.Clinical and experimental nephrology · 2024Article
- Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.Frontiers in pharmacology · 2024Review
- ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion.JCI insight · 2022Article
- EGFR-mediated activation of adipose tissue macrophages promotes obesity and insulin resistance.Nature communications · 2022Article
- CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis.Annals of the rheumatic diseases · 2022Article
- Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review.International journal of molecular sciences · 2022Review
- CCN2 Binds to Tubular Epithelial Cells in the Kidney.Biomolecules · 2022Article
- Key metalloproteinase-mediated pathways in the kidney.Nature reviews. Nephrology · 2021Review
- Kidney GATA3Cellular & molecular immunology · 2021Article
- Single-Cell RNA Sequencing Revealed CD14Frontiers in cell and developmental biology · 2021Article
- Acute Effects on the Human Peripheral Blood Transcriptome of Decompression Sickness Secondary to Scuba Diving.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have identified the EGF receptor (EGFR) ligand amphiregulin (AREG) as an important mediator of inflammatory diseases. Both pro- and anti-inflammatory functions have been described, but the role of AREG in GN remains unknown.
methodsThe nephrotoxic nephritis model of GN was studied in AREG
resultsRenal AREG mRNA was strongly upregulated in murine GN. Renal resident cells were the most functionally relevant source of AREG. Importantly, the observation that knockout mice showed significant amelioration of disease indicates that AREG is pathogenic in GN. AREG enhanced myeloid cell responses
conclusionsAREG is a proinflammatory mediator of GN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.